Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF)

ClinicalTrials.gov ID: NCT02268253

Public ClinicalTrials.gov record NCT02268253. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 21, 2026, 10:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Tagraxofusp (SL-401) in Patients With Chronic Myelomonocytic Leukemia (CMML)

Study identification

NCT ID: NCT02268253
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Stemline Therapeutics, Inc.; Industry
Enrollment: 82 participants

Conditions and interventions

Conditions

Interventions

Tagraxofusp Injection Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 9, 2016
Primary completion: Mar 26, 2023
Completion: Mar 26, 2023
Last update posted: Jan 5, 2025

2016 – 2023

United States locations

U.S. sites: 22
U.S. states: 16
U.S. cities: 21

Facility	City	State	ZIP	Site status
University of California, San Francisco	Clovis	California	93611	—
City of Hope	Duarte	California	91010	—
University of California, Los Angeles	Los Angeles	California	90095	—
Stanford Cancer Institute	Stanford	California	94305	—
Mayo Clinic Florida	Jacksonville	Florida	32224	—
Georgia Cancer Center at Augusta University	Augusta	Georgia	30912	—
Rush University Medical Center	Chicago	Illinois	60612	—
Indiana Blood and Bone Marrow Transplantation	Indianapolis	Indiana	46237	—
University of Kansas Cancer Center	Westwood	Kansas	66205	—
Norton Cancer Institute	Louisville	Kentucky	40207	—
Dana Farber Cancer Institute (DFCI)	Boston	Massachusetts	02114	—
Massachusetts General Hospital	Boston	Massachusetts	02114	—
University of Michigan Health System	Ann Arbor	Michigan	48109	—
Mayo Clinic	Rochester	Minnesota	55905	—
John Theurer Cancer Center	Hackensack	New Jersey	07601	—
University of New Mexico	Albuquerque	New Mexico	87106	—
Roswell Park Cancer Institute	Buffalo	New York	14263	—
Weill Cornell Medical Center	New York	New York	10021	—
Cleveland Clinic Foundation	Cleveland	Ohio	44195	—
The Ohio State University	Columbus	Ohio	43210	—
MD Anderson Cancer Center	Houston	Texas	77030	—
Huntsman Cancer Institute	Salt Lake City	Utah	84112	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02268253, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 5, 2025 · Synced Jul 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02268253 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →